Insights On Enterprise Solutions
-
Aragen Capacity Update July 2025: Large Molecule Drug Substance
7/28/2025
Aragen’s newly built cutting-edge biologics manufacturing facility launches with GMP capabilities from 50L to 2000L—scaling to 5000L soon—with a DP filling line and ADC conjugation suite set to redefine bioproduction in India.
-
PCI Pharma Services Capacity Update July 2025: Fill/Finish
7/28/2025
PCI is positioned to meet the future of sterile pharmaceutical development and manufacturing with cutting-edge technology, and innovative solutions for high-value biologics, complex formulations, and lyophilized drug products.
-
Novartis Contract Manufacturing Capacity Update July 2025: Fill/Finish
7/28/2025
Novartis Contract Manufacturing introduces their fill and finish solutions and capacity. Explore an overview of the aseptic network of Novartis and the capabilities of each site.
-
INCOG BioPharma Services Capacity Update July 2025: Fill/Finish
7/28/2025
Our balanced framework addresses the unique challenges of sterile manufacturing by integrating risk-based decision making with systematic capacity planning.
-
Afton Scientific Capacity Update July 2025: Fill/Finish
7/28/2025
Gain an overview of a new state-of-the-art Groninger filling line’s capabilities, production scale-up timelines, and how this new infrastructure supports product flexibility and long-term growth for our partners in the injectable drug product space.
-
Reducing CMC Risk With Proven Analytical And Formulation Expertise
7/28/2025
Explore real examples of how this outsourcing partner helps drug sponsors through transparency that empowers, integration that simplifies, methods that de-risk, and experience that accelerates.
-
Contract GMP Biologics Analytical Services
7/28/2025
Pedro Morales, Director, Scientific Advisor of Biologics Analytical Services, explores how Catalent delivers tailored solutions through deep expertise and advanced capabilities.
-
Alcami Capacity Update July 2025: Analytical Services
7/28/2025
Alcami’s laboratory services can support many drug substance or drug product modalities, all product phases, and specialty laboratory services, including in-house microbiology, raw materials, and analytical development.
-
MilliporeSigma Capacity Update July 2025: ADC
7/28/2025
MilliporeSigma and Simtra's streamlined collaboration encompasses every stage, including bioconjugation, linker and payload supplies, formulation development, and final fill/finish of drug substance.
-
Integrated ADC Offering: From Concept To Commercialization
7/28/2025
Leveraging deep ADC expertise and experience, successfully develop high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing.